{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:27:01Z","timestamp":1752550021072},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004168","name":"Universit\u00e4t zu L\u00fcbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004168","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Considering the insufficiently controlled spread of new SARS-CoV-2 variants, partially low vaccination rates, and increased risk of a post-COVID syndrome, well-functioning, targeted intervention measures at local and national levels are urgently needed to contain the SARS-CoV-2 pandemic. Surveillance concepts (cross-sectional, cohorts, clusters) need to be carefully selected to monitor and assess incidence and prevalence at the population level. A critical methodological gap for identifying specific risks\/dynamics for SARS-Cov-2 transmission and post-COVID-19-syndrome includes repetitive testing for past or present infection of a defined cohort with simultaneous assessment of symptoms, behavior, risk, and protective factors, as well as quality of life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The ELISA-Study is a longitudinal, prospective surveillance study with a cohort approach launched in Luebeck in April 2020. The first part comprised regular PCR testing, antibody measurements, and a recurrent App-based questionnaire for a population-based cohort of 3000 inhabitants of Luebeck. The follow-up study protocol includes self-testing for antibodies and PCR testing for a subset of the participants, focusing on studying immunity after vaccination and\/or infection and post-COVID-19 symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The ELISA cohort and our follow-up study protocol will enable us to study the effects of a sharp increase of SARS-CoV-2 infections on seroprevalence of Anti-SARS-CoV-2 antibodies, post-COVID-19-symptoms, and possible medical, occupational, and behavioral risk factors. We will be able to monitor the pandemic continuously and discover potential sequelae of an infection long-term. Further examinations can be readily set up on an ad-hoc basis in the future. Our study protocol can be adapted to other regions and settings and is transferable to other infectious diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>DRKS.de, German Clinical Trials Register (DRKS), Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.drks.de\/drks_web\/navigate.do?navigationId=trial.HTML&amp;TRIAL_ID=DRKS00023418\">DRKS00023418<\/jats:ext-link>, Registered on 28 October 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-022-13666-z","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T13:06:28Z","timestamp":1657199188000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study \u2013 a prospective population-based cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Alexander","family":"Balck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bandik","family":"F\u00f6h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Borsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Rahm\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Juliane","family":"Vollstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederike","family":"Waldeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadja","family":"K\u00e4ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Twesten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Mischnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Gillessen-Kaesbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Sina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Taube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hauke","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Katalinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"13666_CR1","unstructured":"WHO Coronavirus (COVID-19) Dashboard. Accessed February 28, 2022. https:\/\/covid19.who.int"},{"issue":"10325","key":"13666_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0140-6736(22)00090-3","volume":"399","author":"C Kuhlmann","year":"2022","unstructured":"Kuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet Lond Engl. 2022;399(10325):625\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(22)00090-3.","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"13666_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMc2119270","volume":"386","author":"S Collie","year":"2022","unstructured":"Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med. 2022;386(5):494\u20136. https:\/\/doi.org\/10.1056\/NEJMc2119270.","journal-title":"N Engl J Med"},{"key":"13666_CR4","unstructured":"SARS-CoV-2 variants of concern and variants under investigation. :43."},{"key":"13666_CR5","unstructured":"RKI COVID-19 Germany. Accessed February 28, 2022. https:\/\/experience.arcgis.com\/experience\/478220a4c454480e823b17327b2bf1d4\/page\/Landkreise\/"},{"issue":"24","key":"13666_CR6","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa2006100","volume":"382","author":"DF Gudbjartsson","year":"2020","unstructured":"Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the icelandic population. N Engl J Med. 2020;382(24):2302\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2006100.","journal-title":"N Engl J Med"},{"key":"13666_CR7","doi-asserted-by":"publisher","unstructured":"Pritsch M, Radon K, Bakuli A, et al. Prevalence and risk factors of infection in the representative COVID-19 cohort Munich. Int J Environ Res Public Health. 2021;18(7). https:\/\/doi.org\/10.3390\/ijerph18073572.","DOI":"10.3390\/ijerph18073572"},{"issue":"1","key":"13666_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-22351-5","volume":"12","author":"NA Aziz","year":"2021","unstructured":"Aziz NA, Corman VM, Echterhoff AKC, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn. Germany Nat Commun. 2021;12(1):1\u201310. https:\/\/doi.org\/10.1038\/s41467-021-22351-5.","journal-title":"Germany Nat Commun"},{"issue":"6","key":"13666_CR9","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/v13061118","volume":"13","author":"R Wagner","year":"2021","unstructured":"Wagner R, Peterhoff D, Beileke S, et al. Estimates and determinants of SARS-Cov-2 seroprevalence and infection fatality ratio using latent class analysis: the population-based Tirschenreuth study in the hardest-hit german county in spring 2020. Viruses. 2021;13(6):1118. https:\/\/doi.org\/10.3390\/v13061118.","journal-title":"Viruses."},{"key":"13666_CR10","doi-asserted-by":"publisher","unstructured":"Santos-H\u00f6vener C, Neuhauser HK, Rosario AS, et al. Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2020;25(47). https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.47.2001752.","DOI":"10.2807\/1560-7917.ES.2020.25.47.2001752"},{"issue":"1","key":"13666_CR11","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1186\/s12889-021-11206-9","volume":"21","author":"M Oberste","year":"2021","unstructured":"Oberste M, Pusch LM, Roth R, et al. Protocol of the cologne corona surveillance (CoCoS) study- a prospective population-based cohort study. BMC Public Health. 2021;21(1):1295\u20136. https:\/\/doi.org\/10.1186\/s12889-021-11206-9.","journal-title":"BMC Public Health"},{"issue":"1","key":"13666_CR12","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1186\/s12889-020-09164-9","volume":"20","author":"K Radon","year":"2020","unstructured":"Radon K, Saathoff E, Pritsch M, et al. Protocol of a population-based prospective COVID-19 cohort study Munich, Germany (KoCo19). BMC Public Health. 2020;20(1):1036\u20139. https:\/\/doi.org\/10.1186\/s12889-020-09164-9.","journal-title":"BMC Public Health"},{"key":"13666_CR13","doi-asserted-by":"publisher","unstructured":"Ward H, Cooke GS, Atchison C, et al. Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: serial cross-sectional studies of 365,000 adults. Lancet Reg Health \u2013 Eur. 2021;4. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100098.","DOI":"10.1016\/j.lanepe.2021.100098"},{"issue":"7821","key":"13666_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41586-020-2488-1","volume":"584","author":"E Lavezzo","year":"2020","unstructured":"Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of a SARS-CoV-2 outbreak in the italian municipality of vo. Nature. 2020;584(7821):425\u20139. https:\/\/doi.org\/10.1038\/s41586-020-2488-1.","journal-title":"Nature."},{"issue":"8","key":"13666_CR15","doi-asserted-by":"publisher","first-page":"ofab379","DOI":"10.1093\/ofid\/ofab379","volume":"8","author":"K Lamba","year":"2021","unstructured":"Lamba K, Bradley H, Shioda K, et al. SARS-CoV-2 cumulative incidence and period seroprevalence: results from a statewide population-based serosurvey in California. Open forum. Infect Dis. 2021;8(8):ofab379. https:\/\/doi.org\/10.1093\/ofid\/ofab379.","journal-title":"Infect Dis"},{"issue":"10","key":"13666_CR16","doi-asserted-by":"publisher","first-page":"e0258255","DOI":"10.1371\/journal.pone.0258255","volume":"16","author":"B Maraqa","year":"2021","unstructured":"Maraqa B, Basha W, Khayyat R, et al. Prevalence of SARS-CoV-2 antibodies in the Palestinian population: a primary health center-based cross-sectional study. PLoS One. 2021;16(10):e0258255. https:\/\/doi.org\/10.1371\/journal.pone.0258255.","journal-title":"PLoS One"},{"issue":"1","key":"13666_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/eji.202149619","volume":"52","author":"E Canto","year":"2022","unstructured":"Canto E, Castro L, Gomes A, Serrano M, et al. Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after infection. Eur J Immunol. 2022;52(1):149\u201360. https:\/\/doi.org\/10.1002\/eji.202149619.","journal-title":"Eur J Immunol"},{"issue":"7","key":"13666_CR18","doi-asserted-by":"publisher","first-page":"e925","DOI":"10.1016\/S2214-109X(21)00173-X","volume":"9","author":"C \u00c1lvarez-Antonio","year":"2021","unstructured":"\u00c1lvarez-Antonio C, Meza-S\u00e1nchez G, Calampa C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and august, 2020: a population-based study. Lancet Glob Health. 2021;9(7):e925\u201331. https:\/\/doi.org\/10.1016\/S2214-109X(21)00173-X.","journal-title":"Lancet Glob Health"},{"key":"13666_CR19","doi-asserted-by":"publisher","unstructured":"Klein C, Borsche M, Balck A, et al. Cohort-based surveillance of SARS-CoV2 transmission mirrors infection rates at the population level: a one-year longitudinal study. MedRxiv Prepr Serv Health Sci. Published online June 2021:2021.05.10.21256966. doi:https:\/\/doi.org\/10.1101\/2021.05.10.21256966.","DOI":"10.1101\/2021.05.10.21256966"},{"key":"13666_CR20","unstructured":"Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Accessed February 28, 2022. https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"key":"13666_CR21","unstructured":"Pendleratlas - Statistik der Bundesagentur f\u00fcr Arbeit. Accessed February 28, 2022. https:\/\/statistik.arbeitsagentur.de\/DE\/Navigation\/Statistiken\/Interaktive-Statistiken\/Pendleratlas\/Pendleratlas-Nav.html"},{"key":"13666_CR22","doi-asserted-by":"publisher","first-page":"104468","DOI":"10.1016\/j.jcv.2020.104468","volume":"129","author":"KG Beavis","year":"2020","unstructured":"Beavis KG, Matushek SM, Abeleda APF, et al. Evaluation of the EUROIMMUN anti-sars-cov-2 ELISA assay for detection of IgA and IgG antibodies. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2020;129:104468. https:\/\/doi.org\/10.1016\/j.jcv.2020.104468.","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"13666_CR23","doi-asserted-by":"publisher","unstructured":"Wu SL, Mertens AN, Crider YS, et al. Substantial underestimation of SARS-CoV-2 infection in the United States. Nat Commun. 2020;11:4507. https:\/\/doi.org\/10.1038\/s41467-020-18272-4.","DOI":"10.1038\/s41467-020-18272-4"},{"key":"13666_CR24","doi-asserted-by":"publisher","unstructured":"F\u00f6h B, Borsche M, Balck A, et al. Complications of nasal and pharyngeal swabs: a relevant challenge of the COVID-19 pandemic? Eur Respir J. 2021;57(4). https:\/\/doi.org\/10.1183\/13993003.04004-2020.","DOI":"10.1183\/13993003.04004-2020"},{"key":"13666_CR25","unstructured":"Gesundheit B f\u00fcr. Das offizielle Dashboard zur Impfkampagne der Bundesrepublik Deutschland Accessed 1 Mar 2022. https:\/\/impfdashboard.de\/"},{"key":"13666_CR26","doi-asserted-by":"crossref","unstructured":"Ritchie H, Mathieu E, Rod\u00e9s-Guirao L, et al. Coronavirus pandemic (COVID-19). Our World Data Published online March 5, 2020. Accessed 28 Feb 2022. https:\/\/ourworldindata.org\/covid-vaccinations","DOI":"10.1038\/s41562-021-01122-8"},{"issue":"10","key":"13666_CR27","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1473-3099(21)00211-5","volume":"21","author":"LC Lund","year":"2021","unstructured":"Lund LC, Hallas J, Nielsen H, et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021;21(10):1373\u201382. https:\/\/doi.org\/10.1016\/S1473-3099(21)00211-5.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-13666-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-022-13666-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-13666-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T13:07:59Z","timestamp":1657199279000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-022-13666-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["13666"],"URL":"https:\/\/doi.org\/10.1186\/s12889-022-13666-z","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"5 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the University of L\u00fcbeck and written-informed consent is obtained by every participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1305"}}